Image2_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.JPEG by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Image7_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.JPEG by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Image5_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.JPEG by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Table3_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.docx by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Table1_The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis.docx by Paolo Comeglio (14195007)

“…</p>Discussion<p>Selvigaltin significantly reduced hepatic inflammation and fibrosis in an HFD rabbit model of MASH following therapeutic dosing for 4 weeks in a dose-dependent manner. These data support the human selvigaltin dose of 100 mg b.i.d. that has been shown to reduce key liver biomarkers during a clinical study in liver cirrhosis.…”

Data Sheet 3_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.xlsx by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Data Sheet 1_Comparison of percutaneous vs. cutdown access for endovascular aortic repair in the treatment of type B aortic dissection: a meta-analysis.pdf by Zhongyou Liang (22617608)

“…In comparison to CEVAR, PEVAR resulted in a reduced hospital length of stay (MD = −2.16 days, 95% CI: −3.05 to −1.27, P < 0.00001), decreased operative time (MD = −40.87 min, 95% CI: −49.72 to −32.02, P < 0.00001), shorter postoperative duration (MD = −1.01 days, 95% CI: −1.56 to −0.45, P = 0.0004), diminished incidence of groin infection (OR = 0.44, 95% CI: 0.30 to 0.65, P < 0.0001), lower occurrence of heart-related complications (OR = 0.76, 95% CI: 0.59 to 1.00, P = 0.05), and reduced incidence of lymphocele (OR = 0.49, 95% CI: 0.24 to 0.98, P = 0.04), but a higher incidence of surgical suture failure (OR = 2.61, 95% CI: 1.52 to 4.50, P = 0.0005) and pseudoaneurysm (OR = 2.64, 95% CI: 1.09 to 6.41, P = 0.03). …”

Table_1_Facial nerve outcome score: a new score to predict long-term facial nerve function after vestibular schwannoma surgery.docx by Giuseppe Di Perna (10305336)

“…The totality of patients with FNOS grade A showed an HB value < 3 at 12 months, decreasing to 70% for those with FNOS grade B, whereas 100% of patients with FNOS grade C showed an HB value ≥ 3. …”

Data Sheet 1_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.xlsx by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Data Sheet 2_Esophageal cancer mortality trends in the United States: a comprehensive longitudinal study (1999–2023) using CDC WONDER data.xlsx by Xuefei Yang (2300221)

“…A significant decline in the mortality rate was observed over this period, with the overall AAMR decreasing from 6.74 to 5.61 per 100,000, corresponding to an AAPC of −0.81* (*p-value < 0.05). …”

Table_1_Epidemiological Trends and Hotspots of Other Infectious Diarrhea (OID) in Mainland China: A Population-Based Surveillance Study From 2004 to 2017.DOC by Can Chen (675404)

“…OID of Tianjin and Beijing presented a decreased trend since 2006. However, the incidence of OID in Guangdong, Guangxi, Hainan and Guizhou showed increased trends through 2004–2017.…”

Data Sheet 2_Comparison of percutaneous vs. cutdown access for endovascular aortic repair in the treatment of type B aortic dissection: a meta-analysis.pdf by Zhongyou Liang (22617608)

“…In comparison to CEVAR, PEVAR resulted in a reduced hospital length of stay (MD = −2.16 days, 95% CI: −3.05 to −1.27, P < 0.00001), decreased operative time (MD = −40.87 min, 95% CI: −49.72 to −32.02, P < 0.00001), shorter postoperative duration (MD = −1.01 days, 95% CI: −1.56 to −0.45, P = 0.0004), diminished incidence of groin infection (OR = 0.44, 95% CI: 0.30 to 0.65, P < 0.0001), lower occurrence of heart-related complications (OR = 0.76, 95% CI: 0.59 to 1.00, P = 0.05), and reduced incidence of lymphocele (OR = 0.49, 95% CI: 0.24 to 0.98, P = 0.04), but a higher incidence of surgical suture failure (OR = 2.61, 95% CI: 1.52 to 4.50, P = 0.0005) and pseudoaneurysm (OR = 2.64, 95% CI: 1.09 to 6.41, P = 0.03). …”

Image_1_Dynamic Changes of Metabolic Syndrome Alter the Risks of Cardiovascular Diseases and All-Cause Mortality: Evidence From a Prospective Cohort Study.TIF by Di He (791903)

Image_2_Dynamic Changes of Metabolic Syndrome Alter the Risks of Cardiovascular Diseases and All-Cause Mortality: Evidence From a Prospective Cohort Study.TIF by Di He (791903)

Image_4_Dynamic Changes of Metabolic Syndrome Alter the Risks of Cardiovascular Diseases and All-Cause Mortality: Evidence From a Prospective Cohort Study.TIF by Di He (791903)

Image_3_Dynamic Changes of Metabolic Syndrome Alter the Risks of Cardiovascular Diseases and All-Cause Mortality: Evidence From a Prospective Cohort Study.TIF by Di He (791903)

Table_2_Association between perioperative plasma transfusion and in-hospital mortality in patients undergoing surgeries without massive transfusion: A nationwide retrospective coho... by Xiaohan Xu (661043)

“…Background<p>An aggressive plasma transfusion is associated with a decreased mortality in traumatic patients requiring massive transfusion (MT). …”

Table_1_Association between perioperative plasma transfusion and in-hospital mortality in patients undergoing surgeries without massive transfusion: A nationwide retrospective coho... by Xiaohan Xu (661043)

“…Background<p>An aggressive plasma transfusion is associated with a decreased mortality in traumatic patients requiring massive transfusion (MT). …”

Image 1_Different lysine-to-methionine ratios in a low-protein diet affect the microbiome and metabolome, influencing the jejunal barrier function in Tibetan sheep.pdf by Fengshuo Zhang (20641988)

“…The feeding trial lasted 100 days, including a 10-day acclimation period and a 90-day experimental period.…”

Table 1_Different lysine-to-methionine ratios in a low-protein diet affect the microbiome and metabolome, influencing the jejunal barrier function in Tibetan sheep.docx by Fengshuo Zhang (20641988)

“…The feeding trial lasted 100 days, including a 10-day acclimation period and a 90-day experimental period.…”